Complete financial analysis of Medios AG (0QB4.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medios AG, a leading company in the Medical – Equipment & Services industry within the Healthcare sector.
- Zhejiang Tailin BioEngineering Co.,Ltd (300813.SZ) Income Statement Analysis – Financial Results
- Krebs Biochemicals & Industries Limited (KREBSBIO.NS) Income Statement Analysis – Financial Results
- HP Inc. (7HP.DE) Income Statement Analysis – Financial Results
- Best Mart 360 Holdings Limited (2360.HK) Income Statement Analysis – Financial Results
- Sterling Check Corp. (STER) Income Statement Analysis – Financial Results
Medios AG (0QB4.L)
About Medios AG
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78B | 1.61B | 1.36B | 626.54M | 516.80M | 327.83M | 253.64M | 133.21M | 134.74 | 4.48K | 326.11 | 35.22K | 1.38M | 1.04M |
| Cost of Revenue | 1.68B | 1.50B | 1.29B | 588.96M | 482.77M | 304.70M | 236.27M | 125.78M | 56.69M | 0.00 | 0.00 | 0.00 | 1.09M | -297.83K |
| Gross Profit | 108.63M | 106.87M | 68.48M | 37.58M | 34.03M | 23.13M | 17.37M | 7.43M | -56.69M | 4.48K | 326.11 | 35.22K | 287.61K | 1.34M |
| Gross Profit Ratio | 6.09% | 6.63% | 5.04% | 6.00% | 6.58% | 7.06% | 6.85% | 5.58% | -42,075,749.78% | 100.00% | 100.00% | 100.00% | 20.92% | 128.70% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 428.00K | 90.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.39M | 4.65M | 3.36M | 3.65M | 2.47M | 1.46M | 1.39M | 366.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.82M | 1.39M | 1.87M | 364.00K | 648.00K | 378.00K | 344.00K | 78.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.21M | 6.04M | 5.23M | 4.02M | 3.12M | 1.84M | 1.73M | 444.00K | 364.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 70.00M | 72.95M | 48.58M | 24.49M | 17.03M | 316.00K | 142.00K | 52.00K | 12.63K | 49.58K | 1.77K | 248.51K | 68.30K | 2.14M |
| Operating Expenses | 78.21M | 78.99M | 53.81M | 28.51M | 20.15M | 15.85M | 10.71M | 8.32M | 172.11K | 93.88K | 196.93K | 248.51K | 68.30K | 2.14M |
| Cost & Expenses | 1.75B | 1.58B | 1.34B | 617.47M | 502.93M | 320.55M | 246.98M | 134.10M | 172.11K | 93.88K | 196.93K | 248.51K | 1.16M | 1.84M |
| Interest Income | 406.00K | 113.00K | 43.00K | 30.00K | 22.75K | 14.52K | 6.69K | 1.97K | 0.00 | 6.96K | 10.56K | 20.62K | 10.20K | 29.51 |
| Interest Expense | 2.41M | 1.26M | 1.73M | 671.00K | 193.90K | 35.06K | 96.49K | 1.29M | 1.52K | 276.20 | 98.42 | 11.12K | 9.63K | -1.28M |
| Depreciation & Amortization | 21.04M | 22.25M | 19.37M | 3.55M | 1.98M | 1.14M | 491.08K | 107.00K | 12.63K | 56.54K | 15.40K | 2.78K | 19.30K | 638.80K |
| EBITDA | 52.82M | 51.33M | 34.68M | 13.12M | 16.40M | 8.56M | 7.29M | -712.00K | 1.10M | -32.86K | -149.76K | -189.89K | 59.38K | -165.16K |
| EBITDA Ratio | 2.96% | 3.19% | 2.55% | 2.09% | 3.15% | 2.61% | 2.88% | -0.55% | -118,257.76% | -732.83% | -51,782.40% | -539.09% | 17.36% | -15.92% |
| Operating Income | 31.37M | 28.97M | 15.26M | 9.54M | 14.39M | 7.40M | 6.80M | -821.49K | -159.34K | -33.13K | -165.16K | -203.79K | 29.85K | 2.44M |
| Operating Income Ratio | 1.76% | 1.80% | 1.12% | 1.52% | 2.78% | 2.26% | 2.68% | -0.62% | -118,257.76% | -738.99% | -50,645.58% | -578.54% | 2.17% | 234.95% |
| Total Other Income/Expenses | -2.00M | -1.15M | -1.69M | -641.00K | -172.00K | -20.54K | -89.80K | -1.29M | -98.89K | 56.43K | 31.44K | 0.00 | 612.00 | -457.31K |
| Income Before Tax | 29.37M | 27.82M | 13.58M | 8.90M | 14.22M | 7.38M | 6.71M | -2.11M | -160.86K | -33.13K | -165.16K | -203.79K | 0.00 | 0.00 |
| Income Before Tax Ratio | 1.65% | 1.73% | 1.00% | 1.42% | 2.75% | 2.25% | 2.65% | -1.59% | -119,388.59% | -738.99% | -50,645.58% | -578.54% | 0.00% | 0.00% |
| Income Tax Expense | 10.56M | 9.49M | 6.17M | 2.84M | 4.46M | 3.05M | 2.58M | 1.36M | -12.63K | 31.13 | -0.14 | -0.62 | 0.00 | 0.00 |
| Net Income | 18.81M | 18.33M | 7.40M | 5.53M | 9.76M | 4.33M | 4.13M | -3.17M | -160.86K | -33.17K | -165.16K | -203.79K | 0.00 | 0.00 |
| Net Income Ratio | 1.05% | 1.14% | 0.55% | 0.88% | 1.89% | 1.32% | 1.63% | -2.38% | -119,388.59% | -739.68% | -50,645.54% | -578.54% | 0.00% | 0.00% |
| EPS | 0.79 | 0.77 | 0.37 | 0.36 | 0.67 | 0.31 | 0.32 | -0.73 | -0.35 | -0.07 | -0.39 | -0.48 | 0.07 | 0.00 |
| EPS Diluted | 0.79 | 0.77 | 0.37 | 0.35 | 0.65 | 0.31 | 0.32 | -0.73 | -0.35 | -0.07 | -0.39 | -0.48 | 0.07 | 0.00 |
| Weighted Avg Shares Out | 23.81M | 23.76M | 20.04M | 15.45M | 14.56M | 13.78M | 12.77M | 4.34M | 458.00K | 455.54K | 425.00K | 425.00K | 455.54K | 14.56M |
| Weighted Avg Shares Out (Dil) | 23.81M | 23.87M | 20.16M | 16.01M | 14.91M | 14.09M | 12.77M | 4.35M | 458.00K | 455.54K | 425.00K | 425.00K | 455.54K | 14.56M |
Source: https://incomestatements.info
Category: Stock Reports